Here are international reviews that all indicated that there was low quality evidence that medical treatments for children are improving those children’s lives. Which was the finding of the Cass report:
NICE finding
arms.nice.org.uk/resources/hub/1070905/attachment
The summary of the conclusion is
Conclusion
The results of the studies that reported impact on the critical outcomes of gender dysphoria and mental health (depression, anger and anxiety), and the important outcomes of body image and psychosocial impact (global and psychosocial functioning), in children and adolescents with gender dysphoria are of very low certainty using modified GRADE. They suggest little change with GnRH analogues from baseline to follow-up.
Canada
https://nationalpost.com/news/canada/transgender-treatments-for-kids
https://archive.ph/fLMxA
"The Canadian team combed the available evidence, pooling the results of research on puberty blockers and gender affirming hormones for children and youth up to age 26. They graded the evidence using a scoring system co-developed by Dr. Gordon Guyatt, a celebrated McMaster scientist who coined the phrase evidence-based medicine.
Article content
After screening 6,736 titles and abstracts involving puberty blockers, only 10 studies were included in their review. While children who received puberty blockers compared to those who don’t score higher on “global function” — quality of life, and general physical and psychological wellbeing — the evidence was of “very low certainty.” Very low, meaning researchers have “very little confidence in the effect estimate” and that the true effect “is likely to be substantially different from the estimate of effect.”
The studies also provided low certainty of evidence on the impact of puberty blockers on depression. While they may decrease depression in “male-to-female participants,” they didn’t decrease depression scores in the female-to-male group. “We are very uncertain about the causal effect of the (drugs) on depression,” the researchers wrote.
“Most studies provided very low certainty of evidence about the outcomes of interest thus, we cannot exclude the possibility of benefit or harm,” they said."
Here are the studies referenced in the article from McMaster University
https://adc.bmj.com/content/archdischild/early/2025/01/24/archdischild-2024-327909.full.pdf
And
https://adc.bmj.com/content/archdischild/early/2025/01/24/archdischild-2024-327921.full.pdf
New Zealand
https://www.health.govt.nz/news/additional-safeguards-for-puberty-blockers
Publication date: 21 November 2024
The Ministry of Health is today releasing an evidence brief and position statement on the use of puberty blockers for gender identity issues and outlining a more cautious approach to their use.
The evidence brief shows a lack of good quality evidence to back the effectiveness and safety of puberty blockers when used for this purpose.
France
The latest from National Academy of Medicine, France. They have issued a press release about treatment for gender disphoria in children and adolescents.
SEGM have translated it, but also linked up the original version.
segm.org/France-cautions-regarding-puberty-blockers-and-cross-sex-hormones-for-youth
Sweden
http://genderreport.ca/the-swedish-u-turn-on-gender-transitioning/
I could also find and link up the same findings for Finland, Norway, Denmark and I believe Germany if I found them. All had teams, iirc, who made the same statement about low quality of evidence as the Cass Report.
I believe there must come a time when it has to be admitted that if a slew of independent country’s teams all found the same low quality of evidence as Dr Hilary Cass, that anyone declaring Cass debunked is just deliberately spreading falsehoods.